Table 1.

Overview of characteristics of patients by treatment arm and trial. The treatment arms not used in the network metaanalysis do not appear; only treatment arms presenting the recommended dosages are reported.

Trial	Treatment Arm	Sex, % F	Mean Age, yrs	Mean Yrs Since Diagnosis	Mean No. Prior DMARD	% Pts Previous DMARD (not MTX)	% Pts Taking NSAID	% Pts Taking Corticosteroids	Mean TJC	Mean SJC	Mean HAQ
AIM	Placebo + MTX	81.7	50.4	8.9	1.2		82.6	68.5	32.3	22.1	1.7
AIM	Abatacept 10 mg/kg every 4 wks + MTX	77.8	51.5	8.5	1.3	NR	85.5	72.1	31	21.4	1.7
Kremer	Placebo + MTX	66	54.7	8.9	NR	21	NR	67.2	29.2	21.8	1.7
Kremer	Abatacept 10 mg/kg every 4 wks + MTX	75	55.8	9.7		16.5		60	30.8	21.3	1.7
ATTEST	Placebo + MTX	87.3	49.4	8.4	1.8		84.5	70	30.3	20.1	1.8
	Abatacept 10 mg/kg every 4 wks + MTX	83.3	49	7.9	1.7	NR	85.3	75.6	31.6	21.3	1.8
	Infliximab 3 mg/kg every 8 wks + MTX	82.4	49.1	7.3	1.7		86.1	71.5	31.7	20.3	1.7
ARMADA	Placebo + MTX	82.3	56	11.1	3	NR	NR	NR	28.7	16.9	1.64
ARMADA	Adalimumab 40 mg every other wk + MTX	74.6	57.2	12.2	2.9				28	17.3	1.55
DE019	Placebo + MTX	73	56.1	10.9	2.4				28.1	19	1.48
DE019	Adalimumab 40 mg every other wk + MTX	76.3	56.1	11	2.4	NR	NR	NR	27.3	19.3	1.45
RAPID I	Placebo + MTX	83.9	52.2	6.2	1.4	NR	NR	NR	29.8	21.2	1.7
RAPID I	CZP 200 mg every other wk + MTX	82.4	51.4	6.1	1.3				30.8	21.7	1.7
RAPID II	Placebo + MTX	84.3	51.5	5.6	1.2	NR	NR	NR	30.4	21.9	1.6
RAPID II	CZP 200 mg every other wk + MTX	83.7	52.2	6.1	1.2				30.1	20.5	1.6
Weinblatt	Placebo + MTX	73	53	13	2.8	NR	80	70	28	17	1.5
Weinblatt	Etanercept 25 mg twice wkly + MTX	90	48	13	2.7		75	53	28	20	1.5
TEMPO	Placebo + MTX	79	53	6.8	2.3		86	64	33.1	22.6	NR
TEMPO	Etanercept 25 mg twice wkly + MTX	74	52.5	6.8	2.3		88	62	34.2	22.1
GO-FORWARD	Placebo + MTX	82	52	6.5	NR	70.7	NR	NR	21	12	1.25
GO-FORWARD	Golimumab 50 mg every 4 wks + MTX	80.9	52	4.5		78.7			26	13	1.38
ATTRACT	Placebo + MTX	80	51	8.9	2.5	NR	72	64	24	19	1.8
ATTRACT	Infliximab 3 mg/kg every 8 wks + MTX	81	56	8.4	2.8		79	63	32	19	1.8

HAQ: Health Assessment Questionnaire; MTX: methotrexate; NSAID: nonsteroidal antiinflammatory drug; RF: rheumatoid factor; SJC: swollen joint count; TJC: tender joint count; NR: not reported.